Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-[18F]fluoro-l-m-tyrosine (6-[18F]FMT) is a radiolabeled noncatecholic amino acid analog used as a diagnostic positron emission tomography (PET) imaging tracer to assess dopaminergic and noradrenergic function in the central nervous system. It serves as a substrate for the enzyme L-aromatic amino acid decarboxylase (AADC), which converts it into 6-[18F]fluorometatyramine. Unlike the more common tracer [18F]FDOPA, 6-[18F]FMT is not a substrate for catechol-O-methyltransferase (COMT), which simplifies kinetic modeling and results in higher contrast images of AADC activity. It is primarily utilized in clinical research to evaluate the integrity of the nigrostriatal pathway in neurodegenerative disorders such as Parkinson's disease and to study noradrenergic dysfunction in the locus coeruleus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-[18f]fluoro-l-m-tyrosine.